KPCB XVI Associates’s Vera Therapeutics VERA Stock Holding History

KPCB XVI Associates’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$23.3M	Hold	1,343,152	–	–	10.38%	3
2021 Q2	$16M	Buy	+1,343,152	New	+$20.9M	7.38%	2

Other funds holding VERA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KPCB XVI Associates's VERA Position: Q3 2021 in Review

KPCB XVI Associates held its Vera Therapeutics (VERA) position steady in Q3 2021 at 1,343,152 shares worth $23.3M. The position accounts for 10.38% of the portfolio, ranked #3.

KPCB XVI Associates first reported a position in VERA in Q2 2021 and has held it in 2 quarters since. 31 funds tracked by Wall St. Rank hold VERA as of Q3 2021.

KPCB XVI Associates held 1,343,152 shares of Vera Therapeutics worth $23.3M as of Q3 2021.
KPCB XVI Associates left its Vera Therapeutics share count unchanged in Q3 2021.
Vera Therapeutics made up 10.38% of KPCB XVI Associates's portfolio in Q3 2021, its #3 holding.
KPCB XVI Associates first reported a position in Vera Therapeutics in Q2 2021 and has held it in 2 quarters since.
31 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2021.

Based on KPCB XVI Associates's 13F filing for Q3 2021, filed 25 Oct 2021.